Literature DB >> 3485346

Pheochromocytoma: detection by unenhanced CT.

D R Radin, P W Ralls, W D Boswell, P M Colletti, S A Lapin, J M Halls.   

Abstract

During a 2 1/2-year period, 10 patients with suspected pheochromocytoma were evaluated by unenhanced computed tomography (CT). Six adrenal masses, one hyperplastic adrenal gland, and two extraadrenal retroperitoneal masses were detected in seven patients; CT of the adrenals and retroperitoneum was normal in three patients. Scintigraphy with iodine-131 metaiodobenzylguanidine (131I-MIBG) was performed in nine of the 10 patients and corroborated the CT findings in all cases. In the three patients with normal CT and 131I-MIBG scintigraphic findings, follow-up assays of serum catecholamines were normal. In six of the seven patients with abnormal CT scans, surgical and pathologic confirmation was obtained; one patient was lost to follow-up after her CT scan. Unenhanced CT is recommended as the initial localizing procedure in patients with suspected pheochromocytoma, thereby avoiding the small but finite risk of hypertensive crisis associated with intravenous injection of urographic contrast medium.

Entities:  

Mesh:

Year:  1986        PMID: 3485346     DOI: 10.2214/ajr.146.4.741

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

Review 1.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

Review 2.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Giant malignant pheochromocytoma in an elderly patient: A case report.

Authors:  Chengquan Ma; Erlin Sun; Bingxin Lu
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.